Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

Next Previous
X
Search
Trial Profile

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imaradenant (Primary) ; Oleclumab (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca; MedImmune

    • Most Recent Events

    • 21 May 2024 Planned End Date changed from 15 Jan 2025 to 15 Jul 2025.
    • 01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
    • 22 Jan 2024 Planned End Date changed from 25 Sep 2024 to 15 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top